Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

SAN ANTONIO, March 26, 2025--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Patients recovering from curative-intent lung cancer surgery with exposure to wildfire disaster have longer lengths of stay in the hospital.

He Zhuguo has experienced the harsh realities of lung cancer diagnosis and treatment. Transitioning from a successful career in the tobacco industry, he faced chemotherapy that he described as ...

Complex cancer and artery treatment at Dutch hospitals is being reformed, and only hospitals with sufficient expertise will ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR ...

Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced non–small cell lung cancer.